UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets

International journal of molecular sciences, 2022-12, Vol.23 (23), p.15287

2022

Volltextzugriff (PDF)

The Omnipresence of DYRK1A in Human Diseases

International journal of molecular sciences, 2022-08, Vol.23 (16), p.9355

2022

Volltextzugriff (PDF)

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome

Frontiers in behavioral neuroscience, 2016-06, Vol.10, p.104-104

2016

Volltextzugriff (PDF)

A novel DYRK1A (Dual specificity tyrosine phosphorylation‐regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro

Journal of neurochemistry, 2015-05, Vol.133 (3), p.440-451

2015

Volltextzugriff (PDF)

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation

The FEBS journal, 2009-11, Vol.276 (21), p.6324-6337

2009

Volltextzugriff (PDF)

Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice

Journal of cellular and molecular medicine, 2023-08, Vol.27 (15), p.2228-2238

2023

Volltextzugriff (PDF)

Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

Aging cell, 2019-10, Vol.18 (5), p.e13000-n/a

2019

Volltextzugriff (PDF)

Activation, regulation, and inhibition of DYRK1A

The FEBS journal, 2011-01, Vol.278 (2), p.246-256

2011

Volltextzugriff (PDF)

A Requirement for Mena, an Actin Regulator, in Local mRNA Translation in Developing Neurons

Neuron (Cambridge, Mass.), 2017-08, Vol.95 (3), p.608-622.e5

2017

Volltextzugriff (PDF)

Structure Activity Relationship Studies around DB18, a Potent and Selective Inhibitor of CLK Kinases

Molecules (Basel, Switzerland), 2022-09, Vol.27 (19), p.6149

2022

Volltextzugriff (PDF)

Upregulated Expression of MicroRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting DYRK1A-Mediated Apoptotic Signaling Cascade

Frontiers in cellular neuroscience, 2019-09, Vol.13, p.399-399

2019

Volltextzugriff (PDF)

Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study

Molecules (Basel, Switzerland), 2022-02, Vol.27 (4), p.1159

2022

Volltextzugriff (PDF)

DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions

International journal of oncology, 2022-04, Vol.60 (4), Article 45

2022

Volltextzugriff (PDF)

Druggable Transient Pockets in Protein Kinases

Molecules (Basel, Switzerland), 2021-01, Vol.26 (3), p.651

2021

Volltextzugriff (PDF)

Design and Microwave Synthesis of New (5Z) 5-Arylidene-2-thioxo-1,3-thiazolinidin-4-one and (5Z) 2-Amino-5-arylidene-1,3-thiazol-4(5H)-one as New Inhibitors of Protein Kinase DYRK1A

Pharmaceuticals (Basel, Switzerland), 2021-10, Vol.14 (11), p.1086-1117

2021

Volltextzugriff (PDF)

Netrin signaling mediates survival of dormant epithelial ovarian cancer cells

eLife, 2024-07, Vol.12

2024

Volltextzugriff (PDF)

Identification of Pharmacophoric Fragments of DYRK1A Inhibitors Using Machine Learning Classification Models

Molecules (Basel, Switzerland), 2022-03, Vol.27 (6), p.1753

2022

Volltextzugriff (PDF)

Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo

International journal of oncology, 2015-06, Vol.46 (6), p.2419-2430

2015

Volltextzugriff (PDF)

p53 downregulates Down syndrome-associated DYRK1A through miR-1246

EMBO reports, 2011-08, Vol.12 (8), p.811-817

2011

Volltextzugriff (PDF)

Diabetic Kinome Inhibitors-A New Opportunity for β-Cells Restoration

International journal of molecular sciences, 2021-08, Vol.22 (16), p.9083

2021

Volltextzugriff (PDF)

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition

Disease models & mechanisms, 2016-08, Vol.9 (8), p.839-848

2016

Volltextzugriff (PDF)

Development of Novel Fluorinated Polyphenols as Selective Inhibitors of DYRK1A/B Kinase for Treatment of Neuroinflammatory Diseases including Parkinson's Disease

Pharmaceuticals (Basel, Switzerland), 2023-03, Vol.16 (3), p.443

2023

Volltextzugriff (PDF)

DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity

eLife, 2024-10, Vol.12

2024

Volltextzugriff (PDF)

Truncated Dyrk1A aggravates neuronal apoptosis by inhibiting ASF‐mediated Bcl‐x exon 2b inclusion

CNS neuroscience & therapeutics, 2024-04, Vol.30 (4), p.e14493-n/a

2024

Volltextzugriff (PDF)

DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD

Journal of biomedical science, 2022-06, Vol.29 (1), p.34-34, Article 34

2022

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Aktive Filter

ThemaKinases

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(76)
Buchkapitel
(2)

Sprache

Englisch
(78)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets

The Omnipresence of DYRK1A in Human Diseases

DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome

A novel DYRK1A (Dual specificity tyrosine phosphorylation‐regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation

Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice

Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

Activation, regulation, and inhibition of DYRK1A

A Requirement for Mena, an Actin Regulator, in Local mRNA Translation in Developing Neurons

Structure Activity Relationship Studies around DB18, a Potent and Selective Inhibitor of CLK Kinases

Upregulated Expression of MicroRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting DYRK1A-Mediated Apoptotic Signaling Cascade

Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study

DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions

Druggable Transient Pockets in Protein Kinases

Design and Microwave Synthesis of New (5Z) 5-Arylidene-2-thioxo-1,3-thiazolinidin-4-one and (5Z) 2-Amino-5-arylidene-1,3-thiazol-4(5H)-one as New Inhibitors of Protein Kinase DYRK1A

Netrin signaling mediates survival of dormant epithelial ovarian cancer cells

Identification of Pharmacophoric Fragments of DYRK1A Inhibitors Using Machine Learning Classification Models

Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo

p53 downregulates Down syndrome-associated DYRK1A through miR-1246

Diabetic Kinome Inhibitors-A New Opportunity for β-Cells Restoration

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition

Development of Novel Fluorinated Polyphenols as Selective Inhibitors of DYRK1A/B Kinase for Treatment of Neuroinflammatory Diseases including Parkinson's Disease

DYRK1A interacts with the tuberous sclerosis complex and promotes mTORC1 activity

Truncated Dyrk1A aggravates neuronal apoptosis by inhibiting ASF‐mediated Bcl‐x exon 2b inclusion

DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD

Aktive Filter

Suchergebnisse filtern